TERN
Terns Pharmaceuticals, Inc.
No data for this timeframe.
Vol
Analyst ConsensusHold (35%)
Inst. Holders50 funds
Inst. Value$3.7B
Inst. Activity31 buys / 19 sells
Insider Activity0B / 2S
Insider Net $-$599.8K
SEC Reports6
Press Releases2
Recent Activity
May 18, 2026
earnings_calendar
TERN Q1 2026 Earnings Scheduled — 2026-05-18
May 15, 2026
SEC
Terns Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective May 15, 2026.
15-12G — Impact 8/10
May 8, 2026
SEC
Terns Pharmaceuticals' automatic shelf registration statement (S-3ASR) filed on December 9, 2025, became effective on Ma
EFFECT — Impact 4/10
May 5, 2026
SEC
Terns Pharmaceuticals has been acquired by Merck Sharp & Dohme in a completed all-cash merger. The tender offer expired
8-K — Impact 8/10
May 5, 2026
Insider
Burroughs Amy L. disposed of 146,614 shares
Chief Executive Officer @ $53.00 ($7.8M)
May 5, 2026
Insider
Burroughs Amy L. disposed of 150,000 shares
Chief Executive Officer @ $53.00 ($8.0M)
May 5, 2026
Insider
Burroughs Amy L. disposed of 955,534 shares
Chief Executive Officer
Inst.
Avoro Capital Advisors LLC — ADD
5,695,000 shares ($300.2M)
Price Targets
$53.00
+0.1% upside
Hold
Current $52.95
Low $53.00
Median $53.00
High $53.00
4 analysts
$53.00
$53.00
Analyst Ratings
2Strong Buy
4Buy
11Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 27, 2026 | Oppenheimer | DOWNGRADE | Outperform → Perform |
| Apr 14, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Mar 31, 2026 | Truist Securities | DOWNGRADE | Buy → Hold |
| Mar 30, 2026 | Barclays | DOWNGRADE | Overweight → Equal-Weight |
| Mar 26, 2026 | Citizens | DOWNGRADE | Market Outperform → Market Perform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.26 ▲ +2.9% | $-0.32 — $-0.22 | -1% YoY | 3 |
| Next Q | $-0.28 ▲ +3.3% | $-0.34 — $-0.24 | -6% YoY | 3 |
| Current FY | $-1.24 ▼ -16.8% | $-1.48 — $-1.00 | -20% YoY | 2 |
| Next FY | $-1.56 ▼ -5.7% | $-1.82 — $-1.29 | -26% YoY | 3 |
Latest Reports
BEARISH
15-12G
8/10
Terns Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective May 15, 2026.
May 15, 2026
NEUTRAL
EFFECT
4/10
Terns Pharmaceuticals' automatic shelf registration statement (S-3ASR) filed on December 9, 2025, became effective on Ma
May 8, 2026
BULLISH
Press
8/10
Terns Pharmaceuticals announced FDA Breakthrough Therapy Designation for TERN-701, an oral BCR::ABL1 inhibitor, in chron
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BlackRock, Inc. | $504.5M | — |
| MORGAN STANLEY | $340.0M | — |
| Avoro Capital Advisors LLC | $300.2M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $229.6M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 5, 2026 | Burroughs Amy | U | $7.8M |
| May 5, 2026 | Burroughs Amy | D | $8.0M |
| May 5, 2026 | Burroughs Amy | D | $0.00 |
| May 5, 2026 | Gengos Andrew | U | $2.1M |
| May 5, 2026 | Gengos Andrew | D | $3.6M |
50 institutional holders with $3.7B total value (70,885,316 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, MORGAN. Net buying activity: 31 institutions added/increased vs 19 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 9,569,585 | $504.5M | 13.5% | — |
| 3 | MORGAN STANLEY | 6,449,140 | $340.0M | 9.1% | — |
| 4 | Avoro Capital Advisors LLC | 5,695,000 | $300.2M | 8.1% | ADD +30.9% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4,355,482 | $229.6M | 6.2% | — |
| 6 | Holocene Advisors, LP | 4,115,828 | $217.0M | 5.8% | ADD +48.3% |
| 7 | CITADEL ADVISORS LLC | 3,218,810 | $169.7M | 4.6% | — |
| 8 | BALYASNY ASSET MANAGEMENT L.P. | 2,779,445 | $146.5M | 3.9% | DOUBLED +211.6% |
| 9 | FRANKLIN RESOURCES INC | 2,409,019 | $127.0M | 3.4% | — |
| 10 | STATE STREET CORP | 2,139,662 | $112.8M | 3.0% | — |
| 11 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,124,817 | $112.0M | 3.0% | TRIM -61.7% |
| 12 | CAPITOLIS LIQUID GLOBAL MARKETS LLC | 1,975,800 | $104.2M | 2.8% | TRIM -35.1% |
| 13 | Pictet Asset Management Holding SA | 1,655,575 | $87.3M | 2.3% | — |
| 14 | JANUS HENDERSON GROUP PLC | 1,470,057 | $77.5M | 2.1% | TRIM -56.5% |
| 15 | Capital International Investors | 1,424,504 | $75.1M | 2.0% | ADD +34.4% |
| 16 | DIMENSIONAL FUND ADVISORS LP | 1,247,845 | $65.8M | 1.8% | — |
| 17 | BALYASNY ASSET MANAGEMENT L.P. | 1,108,000 | $58.4M | 1.6% | DOUBLED +211.6% |
| 18 | GOLDMAN SACHS GROUP INC | 1,106,961 | $58.4M | 1.6% | — |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,016,400 | $53.6M | 1.4% | — |
| 20 | MARSHALL WACE, LLP | 927,600 | $48.9M | 1.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | ADD | 4,350,000 | 5,695,000 | +30.9% | $300.2M | 2026-Q1 |
| Holocene Advisors, LP | ADD | 2,775,493 | 4,115,828 | +48.3% | $217.0M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 891,903 | 2,779,445 | +211.6% | $146.5M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 5,550,000 | 2,124,817 | -61.7% | $112.0M | 2026-Q1 |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | TRIM | 3,045,200 | 1,975,800 | -35.1% | $104.2M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | TRIM | 3,379,569 | 1,470,057 | -56.5% | $77.5M | 2026-Q1 |
| Capital International Investors | ADD | 1,060,000 | 1,424,504 | +34.4% | $75.1M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | TRIM | 1,515,400 | 924,562 | -39.0% | $48.7M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 553,609 | 811,636 | +46.6% | $42.8M | 2026-Q1 |
| Verition Fund Management LLC | DOUBLED | 12,765 | 802,293 | +6185.1% | $42.3M | 2026-Q1 |
| TORONTO DOMINION BANK | TRIM | 1,400,802 | 781,800 | -44.2% | $41.2M | 2026-Q1 |
| Nuveen, LLC | TRIM | 1,078,157 | 772,592 | -28.3% | $40.7M | 2026-Q1 |
| JENNISON ASSOCIATES LLC | NEW | — | 501,419 | — | $26.4M | 2026-Q1 |
| Neuberger Berman Group LLC | NEW | — | 480,740 | — | $25.3M | 2026-Q1 |
| LMR Partners LLP | NEW | — | 400,000 | — | $21.1M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 137,478 | 384,681 | +179.8% | $20.3M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 788,659 | 375,505 | -52.4% | $19.8M | 2026-Q1 |
| Hudson Bay Capital Management LP | DOUBLED | 81,034 | 360,878 | +345.3% | $19.0M | 2026-Q1 |
| SOROS FUND MANAGEMENT LLC | NEW | — | 321,905 | — | $17.0M | 2026-Q1 |
| Invesco Ltd. | TRIM | 606,247 | 304,487 | -49.8% | $16.1M | 2026-Q1 |
| FMR LLC | TRIM | 1,026,863 | 295,622 | -71.2% | $15.6M | 2026-Q1 |
| Magnetar Financial LLC | NEW | — | 281,614 | — | $14.8M | 2026-Q1 |
| GABELLI FUNDS LLC | NEW | — | 271,857 | — | $14.3M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 73,246 | 267,520 | +265.2% | $14.1M | 2026-Q1 |
| Blackstone Inc. | TRIM | 476,754 | 231,282 | -51.5% | $12.2M | 2026-Q1 |
9 unique insiders with 22 transactions. Net insider value: -$599.8K ($0.00 bought, $599.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 5, 2026 | Burroughs Amy L. | Chief Executive Officer | U | 146,614 | $53.00 | $7.8M |
| May 5, 2026 | Burroughs Amy L. | Chief Executive Officer | D | 150,000 | $53.00 | $8.0M |
| May 5, 2026 | Burroughs Amy L. | Chief Executive Officer | D | 955,534 | — | — |
| May 5, 2026 | Gengos Andrew | Chief Financial Officer | U | 40,503 | $53.00 | $2.1M |
| May 5, 2026 | Gengos Andrew | Chief Financial Officer | D | 68,750 | $53.00 | $3.6M |
| May 5, 2026 | Gengos Andrew | Chief Financial Officer | D | 750,000 | — | — |
| May 5, 2026 | Kuriakose Emil | Chief Medical Officer | U | 24,562 | $53.00 | $1.3M |
| May 5, 2026 | Kuriakose Emil | Chief Medical Officer | D | 81,953 | $53.00 | $4.3M |
| May 5, 2026 | Kuriakose Emil | Chief Medical Officer | D | 485,000 | — | — |
| May 5, 2026 | KINDLER JEFFREY B | Director | D | 32,000 | — | — |
| May 5, 2026 | Tripuraneni Radhika | Director | D | 64,000 | — | — |
| May 5, 2026 | Quigley Jill M. | Director | D | 45,000 | — | — |
| May 5, 2026 | Azelby Robert | Director | D | 90,000 | — | — |
| Apr 1, 2026 | Kuriakose Emil | Chief Medical Officer | SELL | 942 | $52.75 | $49.7K |
| Mar 16, 2026 | Burroughs Amy L. | Chief Executive Officer | EXERCISE | 14,583 | $4.64 | $67.7K |
| Mar 16, 2026 | Burroughs Amy L. | Chief Executive Officer | SELL | 11,813 | $46.57 | $550.1K |
| Feb 1, 2026 | FELLOWS DAVID A | Director | AWARD | 2,828 | — | — |
| Feb 1, 2026 | KINDLER JEFFREY B | Director | AWARD | 1,697 | — | — |
| Feb 1, 2026 | Quigley Jill M. | Director | AWARD | 1,697 | — | — |
| Feb 1, 2026 | Azelby Robert | Director | AWARD | 1,697 | — | — |
| Feb 1, 2026 | Tripuraneni Radhika | Director | AWARD | 1,697 | — | — |
| Feb 1, 2026 | Turner Heather D | Director | AWARD | 1,697 | — | — |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 1 mixed, 2 neutral. Avg impact: 7.0/10.
BEARISH
15-12G
8/10
Terns Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), eff
May 15, 2026
NEUTRAL
EFFECT
4/10
Terns Pharmaceuticals' automatic shelf registration statement (S-3ASR) filed on December 9, 2025, be
May 8, 2026
NEUTRAL
8-K
8/10
Terns Pharmaceuticals has been acquired by Merck Sharp & Dohme in a completed all-cash merger. The t
May 5, 2026
BEARISH
25-NSE
9/10
Nasdaq filed a Form 25-NSE to delist Terns Pharmaceuticals (TERN) common stock, effective immediatel
May 5, 2026
BULLISH
8-K
8/10
Terns Pharmaceuticals announced that the FDA granted Breakthrough Therapy Designation (BTD) to its d
Apr 27, 2026
MIXED
INST-CLUSTER
5/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and Schwab — increased their positio
Feb 28, 2026
Current analyst consensus: Sell (35% buy). Based on 17 analysts: 2 strong buy, 4 buy, 11 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$53.00 mean target
+0.1% upside
Hold (3.00)
$53.00 Low
$53.00 High
| Metric | Value |
|---|---|
| Current Price | $52.95 |
| Target Low | $53.00 |
| Target Mean | $53.00 |
| Target Median | $53.00 |
| Target High | $53.00 |
| # Analysts | 4 |
| Recommendation | Hold (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.26 | $-0.32 | $-0.22 | -1.3% | +2.9% | 2↑ 1↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-06-30 |
$-0.28 | $-0.34 | $-0.24 | -6.4% | +3.3% | 3↑ 1↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-1.24 | $-1.48 | $-1.00 | -20.4% | -16.8% | 3↑ 1↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-1.56 | $-1.82 | $-1.29 | -25.5% | -5.7% | 2↑ 1↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.263 | |
| 7d ago | $-0.271 | +0.008 |
| 30d ago | $-0.271 | +0.008 |
| 60d ago | $-0.287 | +0.024 |
| 90d ago | $-0.303 | +0.040 |
7 analyst firms have rated this stock: 0 upgrades, 6 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 27, 2026 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Apr 14, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 31, 2026 | Truist Securities | DOWNGRADE | Buy | Hold |
| Mar 30, 2026 | Barclays | DOWNGRADE | Overweight | Equal-Weight |
| Mar 26, 2026 | Citizens | DOWNGRADE | Market Outperform | Market Perform |
| Mar 26, 2026 | TD Cowen | DOWNGRADE | Buy | Hold |
| Mar 25, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 11 | 0 | 0 | 35% | |
| May 1, 2026 | 2 | 4 | 11 | 0 | 0 | 35% | |
| Apr 1, 2026 | 5 | 4 | 8 | 0 | 0 | 53% | |
| Mar 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 5 | 11 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 5 | 11 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 18, 2026
earnings_calendar
TERN Q1 2026 Earnings Scheduled — 2026-05-18
May 6, 2026
earnings_calendar
TERN Q1 2026 Earnings Scheduled — 2026-05-06
Apr 29, 2026
short_interest
FTD: TERN — 22,564 shares ($1.2M) failed to deliver
Settlement: 20260429, Price: $52.94, FTD Value: $1,194,538.16, TERNS PHARMACEUTICALS INC COM
Apr 27, 2026
fda
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) wit
Apr 13, 2026
short_interest
FTD: TERN — 201,609 shares ($10.6M) failed to deliver
Settlement: 20260413, Price: $52.63, FTD Value: $10,610,681.67, TERNS PHARMACEUTICALS INC COM
Apr 2, 2026
other
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
<p align="left">FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a cli
Mar 31, 2026
earnings_calendar
TERN Q4 2025 Earnings After Market Close — 2026-03-31
Mar 25, 2026
m_and_a
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
<p align="center"><strong>Terns’ lead candidate TERN-701 is an investigational oral </strong><strong>allosteric BCR::ABL1 tyrosine kinase inhibitor c<
Mar 12, 2026
short_interest
FTD: TERN — 90,061 shares ($4.2M) failed to deliver
Settlement: 20260312, Price: $46.78, FTD Value: $4,213,053.58, TERNS PHARMACEUTICALS INC COM
Feb 6, 2026
short_interest
FTD: TERN — 55,428 shares ($2.0M) failed to deliver
Settlement: 20260206, Price: $35.34, FTD Value: $1,958,825.52, TERNS PHARMACEUTICALS INC COM